Abstract
Sialyl-Lewis a (sLea), mainly expressed on cancer cells of the digestive organs,2 has been known as an important cancer-associated carbohydrate antigen.3 Very recently, it has been demonstrated4–9 that the (sLea) antigen is one of the possible ligands recognized by selectins, a family of lectin-type cell adhesion molecules (LEC-CAMS). These findings suggest that the (sLea) antigen may be involved in the process of hematogeneous metastasis of cancer cells. 1-Deoxynojirimycin (DNJ) and related compounds have been shown10 not only to be potent inhibitors of a-glycosidases and glycoprotein-processing enzymes, but also to be of potential clinical value as antidiabetic, antineoplastic and anti-HIV agents. In a preceding paper we reported the synthesis of DNJ-containing sialyl-Lewis x antigen which has been identified as a major carbohydrate ligand for leukocyte adhesion on vascular endothelium mediated by selectins. The present paper describes the first synthesis of l-deoxynojirimycin- containing cancer-associated (sLea) antigen and related compounds.